Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.65
- Piotroski Score 6.00
- Grade Equal-Weight
- Symbol (MRK)
- Company Merck & Co., Inc.
- Price $101.18
- Changes Percentage (0.45%)
- Change $0.45
- Day Low $100.85
- Day High $101.69
- Year High $134.63
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
- Last Earnings 07/23/2024
- Ex-Dividend for 5/16 Dividend 09/16/2024
- Dividend Payable 10/07/2024
- Today N/A
- Next Earnings (Estimated) 02/03/2025
- Fiscal Year End N/A
- Average Stock Price Target $132.00
- High Stock Price Target $294.00
- Low Stock Price Target $80.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.91
- Trailing P/E Ratio 143.59
- Forward P/E Ratio 143.59
- P/E Growth 143.59
- Net Income $365.00 M
Income Statement
Quarterly
Annual
Latest News of MRK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is MRK Stock Undervalued At $100?
Merck's Q3 results surpassed estimates with revenue of $16.7 billion and adjusted earnings of $1.57 per share. Keytruda sales drove growth, but one-time charges impacted earnings outlook....
By Forbes | 21 hours ago -
Newmark Group Inc (NMRK) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Newmark expects strong office leasing performance with a robust pipeline and anticipates growth in leasing commissions. Retail and industrial sectors are active, with data centers and cold storage sho...
By Yahoo! Finance | 1 day ago -
Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now?
Interest in weight-loss drugs like Ozempic and Wegovy is driving significant growth. GLP-1 drugs may reduce opioid and alcohol addiction rates and are being explored for treating Alzheimer's and other...
By Yahoo! Finance | 3 days ago
